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Case ReportMicrodeletion in a FAAH pseudogene identified in a patient with high
anandamide concentrations and pain insensitivity
Abdella M. Habib1,2, Andrei L. Okorokov1, Matthew N. Hill3, Jose T. Bras4,5,
Man-Cheung Lee1,6,7, Shengnan Li1, Samuel J. Gossage1,
Marie van Drimmelen8, Maria Morena3, Henry Houlden5, Juan D. Ramirez9,
David L. H. Bennett9, Devjit Srivastava10,* and James J. Cox1,*
1Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London,
London, UK, 2College of Medicine, Member of Qatar Health Cluster, Qatar University, Doha, Qatar, 3Hotchkiss
Brain Institute, Departments of Cell Biology and Anatomy and Psychiatry, University of Calgary, Calgary, AB,
Canada, 4UK Dementia Research Institute at UCL, London, UK, 5Department of Molecular Neuroscience,
Institute of Neurology, University College London, London, UK, 6University Division of Anaesthesia,
University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge, UK, 7Department of Anesthesia
and Perioperative Care, University of California, San Francisco, San Francisco, CA, USA, 8Department of
Pathology, Raigmore Hospital, Inverness, UK, 9Nuffield Department of Clinical Neurosciences, University of
Oxford, Oxford, UK and 10Department of Anaesthesia, Raigmore Hospital, Inverness, UK
*Corresponding authors. E-mails: dev.srivastava@nhs.net, j.j.cox@ucl.ac.ukSummary
Thestudyof rare familieswith inheritedpain insensitivity can identifynewhuman-validatedanalgesicdrug targets.Here, a
66-yr-old female presented with nil requirement for postoperative analgesia after a normally painful orthopaedic hand
surgery (trapeziectomy). Further investigations revealed a lifelong history of painless injuries, such as frequent cuts and
burns,whichwere observed to heal quickly.We report the causativemutations for this newpain insensitivity disorder: the
co-inheritance of (i) a microdeletion in dorsal root ganglia and brain-expressed pseudogene, FAAH-OUT, which we cloned
from the fatty-acid amide hydrolase (FAAH) chromosomal region; and (ii) a common functional single-nucleotide poly-
morphism in FAAH conferring reduced expression and activity. Circulating concentrations of anandamide and related
fatty-acid amides (palmitoylethanolamide and oleoylethanolamine) that are all normally degraded by FAAH were signifi-
cantly elevated in peripheral blood compared with normal control carriers of the hypomorphic single-nucleotide poly-
morphism. The genetic findings and elevated circulating fatty-acid amides are consistent with a phenotype resulting from
enhancedendocannabinoidsignallinganda lossof functionof FAAH.Our resultshighlightpreviouslyunknowncomplexity
at the FAAH genomic locus involving the expression of FAAH-OUT, a novel pseudogene and long non-coding RNA. These
data suggest new routes to develop FAAH-based analgesia by targeting of FAAH-OUT, which could significantly improve the
treatment of postoperative pain and potentially chronic pain and anxiety disorders.
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e250 - Habib et al.Fatty-acid amide hydrolase (FAAH) is the major catabolic
enzyme for a range of bioactive lipids called fatty-acid
amides (FAAs).1,2 These FAAs include N-acyl ethanolamines,
such as anandamide (AEA), that act as endogenous
ligands for cannabinoid receptors (i.e. endocannabinoids).
Other substrates of FAAH include palmitoylethanolamide
(PEA), oleoylethanolamine (OEA), and N-acyl-taurines.
2-Arachidonoylglycerol (2-AG) is another related endocanna-
binoid and FAA, but is metabolised mostly by mono-
acylglycerol lipase (MAGL). AEA has roles in nociception,
fear-extinction memory, anxiety, and depression.3,4 FAAH
knockout mice have elevated brain concentrations of AEA,
display an analgesic phenotype in response to acute thermal
stimuli, and show reduced pain in formalin and carrageenan
inflammatory models.5,6 FAAH is therefore an attractive
drug target for treating pain, anxiety, and depression,
although recent clinical trials with FAAH inhibitors were
unsuccessful.7,8
The human FAAH gene contains a commonly carried
hypomorphic single-nucleotide polymorphism (SNP) (C385A;
rs324420; C allele frequency 74%, A 26%) that significantly
reduces the activity of the FAAH enzyme.9 Genetic association
studies have investigated the link between this and other
FAAH SNPs and pain sensitivity.10e12 Notably, homozygous
carriers of the hypomorphic SNP (A allele) in a cohort of
women undergoing breast cancer surgery were less sensitive
to cold pain and had a reduced need for postoperative
analgesia.10 Furthermore, a mouse knock-in model of the
human SNP showed that both the mouse and human SNP
carriers display enhanced fear-extinction learning and
decreased anxiety-linked behaviours.13 Here, we describe a
pain-insensitive patient with a non-anxious disposition pre-
senting with a novel genetic disorder associated with loss of
function of FAAH.Case report
A 66-yr-old Caucasian female presented to Raigmore Hospital
in Inverness, Scotland for orthopaedic surgery, specifically a
trapeziectomy with ligament reconstruction and tendon
interposition and extensor pollicis longus realignment after a
diagnosis of bilateral pantrapezial osteoarthritis. There was
significant deformity and deterioration in the use of the right
thumb, which was reported as painless before operation. The
pre-assessment note classed her as ASA physical status 1, but
highlighted that she had a history of vomiting after intake of
morphine.
For the surgery, she received general anaesthesia with an
ultrasound-guided axillary nerve block. She received fentanyl
50 mg i.v., propofol 200 mg i.v., ondansetron 4 mg i.v. intra-
operatively, and levobupivacaine 0.25% (20 ml) for the axillary
nerve block. After operation, her pain intensity score was 0/10
until the next day when she was discharged home. The only
postoperative analgesic she received in hospital was paracet-
amol 1 g i.v. in the PACU on the day of her surgery. She
also received cyclizine 50 mg i.v. twice. Extraordinarily, she
required no postoperative analgesics other than paracetamol
for this known painful surgery (trapeziectomy), even after the
axillary nerve block had worn off. She showed no pain from
pinching or from peripheral i.v. cannula manipulation, which
led to further investigations.
The patient had been diagnosed with osteoarthritis of the
hip, which she reported as painless, which was not consistent
with the severe degree of joint degeneration. At 65 yr of age,she had undergone a hip replacement and was administered
only paracetamol 2 g orally on Postoperative days 1 and 2,
reporting that she was encouraged to take the paracetamol,
but that she did not ask for any analgesics. She was also
administered a single dose of morphine sulphate 10 mg orally
on the first postoperative evening that caused severe nausea
and vomiting for 2 days. After operation, her pain intensity
scores were 0/10 throughout except for one score of 1/10 on the
first postoperative evening. Her past surgical history was
notable for multiple varicose vein and dental procedures for
which she has never required analgesia. She also reported a
long history of painless injuries (e.g. suturing of a laceration
and left wrist fracture) for which she did not use analgesics.
She reported numerous burns and cuts without pain
(Supplementary Fig. S1), often smelling her burning flesh
before noticing any injury, and that these wounds healed
quickly with little or no residual scar. She reported eating
Scotch bonnet chilli peppers without any discomfort, but a
short-lasting ‘pleasant glow’ in her mouth. She described
sweating normally in warm conditions.
The patient lives with her husband, and has a daughter and
a son from her previous marriage. Her family history is unre-
markable for neuropathy or painful conditions. Her mother
and daughter appear to perceive pain normally. Her father
(now deceased) had little requirement for pain killers. Her son
also reports of having some degree of pain insensitivity, but
not to the same extent as her. She does not take any medica-
tion at present, and is fit and active with nomedical conditions
apart from arthritis (Supplementary Fig. S2). She is talkative
and happy with an optimistic outlook. On the Generalized
Anxiety Disorder-7 anxiety questionnaire taken at age 70, she
scored 0/21, classified as mild (the lowest category).14
Likewise, on the Patient Health Questionnaire-9 for depres-
sion, she scored 0/29, classified as mild.15 She reported long-
standing memory lapses (e.g. frequently forgetting words
mid-sentence and placement of keys). She also reported never
panicking, not even in dangerous or fearful situations, such as
in a recent road traffic accident.
After the painless trapeziectomy surgery and a history of
‘painless operations’, she was referred to and further investi-
gated by pain genetics teams from University College London
and the University of Oxford at age 67 yr. Ethical approval was
granted from both institutions, and written consent taken
from the patient, her two children, and mother. On clinical
examination, she had multiple scars around the arms and on
the back of her hands. Quantitative sensory testing
(Supplementary Fig. S3) demonstrated hyposensitivity to
noxious heat both in the hands and feet (see Supplementary
data for further clinical details).Genetic tests identify a microdeletion downstream of
FAAH
Genomic DNA was isolated from the patient, her two chil-
dren, and her mother for exome sequencing. After filtering of
variants, four candidate mutations in the patient and her son
were identified, but none were considered likely to be causal
for the phenotype (see Supplementary data). We broadened
our genetic analyses and searched for cytogenetic copy
number changes across the genome using the CytoScan™ HD
Array (Thermo Fisher Scientific, UK). This identified an ~8 kb
heterozygous microdeletion on Chromosome 1 that began
~4.7 kb downstream from the 30 end of FAAH (Fig 1a;
Supplementary Fig. S4). Polymerase chain reaction and
Fig 1. (a) Genomic map showing FAAH, FAAH-OUT, and microdeletion. Human chromosome 1 showing the gene footprints of FAAH and
FAAH-OUT. Exons are denoted by blue boxes and the direction of transcription shown by arrows. FAAH single-nucleotide polymorphism
(SNP) rs324420 maps to Exon 3 (indicated by an asterisk). The 8131 bp microdeletion detected in the patient is shown flanked by Alu
repeated sequences (green boxes), which likely predispose the genomic region to rearrangements. The promoter region and Exons 1 and 2
of FAAH-OUT map to the deleted sequence. (b) Genotype summary. The proband carries both the FAAH-OUT microdeletion and the
hypomorphic FAAH SNP, and displayed a full hypoalgesic phenotype. Her son carries the FAAH-OUT microdeletion and had a partial
hypoalgesic phenotype. Neither the unaffected mother nor daughter carries the microdeletion. (cef) Circulating anandamide
(AEA), palmitoylethanolamide (PEA), oleoylethanolamine (OEA), and 2-arachidonoylglycerol (2-AG) concentrations. Concentrations of AEA,
PEA, OEA, and 2-AG were measured by mass spectrometry from blood samples obtained from the patient and four unrelated normal
controls. AEA, PEA, and OEA are substrates for FAAH; 2-AG is not. Controls A and B are homozygous wild type for the hypomorphic SNP;
Controls C and D are heterozygous carriers. Average values for the controls were AEA (1.2 pmol ml1), PEA (43.4 pmol ml1), OEA (5.1 pmol
ml1), and 2-AG (42.2 pmol ml1), which is consistent with previous data using a similar measurement protocol.16 Average values for the
patient (two measurements) were AEA (2.0 pmol ml1), PEA (113.1 pmol ml1), OEA (17.3 pmol ml1), and 2-AG (45 pmol ml1).
FAAH-OUT deletion and pain insensitivity - e251sequencing analyses confirmed that the patient co-inherited
the microdeletion and FAAH hypomorphic SNP allele
(rs324420) (Fig 1b). Her unaffected mother and daughter did
not carry the microdeletion, but her son, who also has some
pain-sensitivity deficits, was heterozygous for the
microdeletion (Supplementary Fig. S5), but did not carry the
hypomorphic SNP allele. One Colombian male (HG01353)
(pain phenotype unknown) out of 5008 alleles screened in the
1000 Genomes Project also carries a similar-sized micro-
deletion (esv3585936 in Supplementary Table S1), but is ho-
mozygous wild type for FAAH SNP rs324420.
Given the extraordinary phenotype in the patient and the
vicinity of themicrodeletion to FAAH, we investigated how the
microdeletion could be pathogenic. Molecular cloning experi-
ments (see Supplementary data) identified novel 50exons of an
expressed FAAH pseudogene, herein called FAAH-OUT (2.845
kb cDNA; KU950306), that mapped to within the microdeletion
(Fig 1a). Tissue expression analyses showed FAAH-OUT to be
expressed in a wide range of tissues, including fetal and adult
brain, and in dorsal root ganglia (DRG; Supplementary Fig. S6).
FAAH-OUT likely encodes a long non-coding RNA
(Supplementary Fig. S7). We considered that themicrodeletion
may negate the normal function of FAAH through a reductionin neural expression of FAAH-OUT or through loss of a critical
genomic regulatory element for FAAH, and hence, obtained
blood samples to measure FAAH-regulated lipids.Elevated FAA concentrations in blood
To determine the effects of carrying both the microdeletion in
FAAH-OUT and the hypomorphic FAAH SNP, we measured the
circulating FAA concentrations from blood samples from the
patient and four controls, two of which were heterozygous
carriers of the SNP. Circulating concentrations of AEA were
increased by 70% and of OEA and PEA approximately tripled
compared with controls (Fig. 1cee). The concentrations of
2-AG, another endocannabinoid that is mainly degraded by
MAGL and not FAAH, were largely unaltered (Fig 1f). These
results are consistent with FAAH having a significant loss of
function in the patient.Discussion
The endocannabinoid system is an important physiological
system that performs a wide array of homeostatic functions
and is important for pain perception.17 FAAH is a critical
e252 - Habib et al.enzyme for the breakdown of a range of bioactive lipids
(including the endocannabinoid AEA and related FAAs and N-
acyl-taurines) with diverse physiological roles. Mouse model-
ling of FAAH loss of function mutations and pharmacological
inhibition studies have shown a range of phenotypes,
including hypoalgesia, accelerated skin wound healing,
enhanced fear-extinction memory, reduced anxiety, and
short-term memory deficits.6,13,18e21 Furthermore, human
hypomorphic FAAH SNPs are associated with a reduced need
for postoperative analgesia, increased postoperative nausea
and vomiting induced by opioids, and decreased anxiety-
linked behaviours.10,13,16,22e24
Here, we report a new human genetic disorder in a patient
with hypoalgesia, altered fear and memory symptoms, and a
non-anxious disposition. This disorder is attributable to co-
inheritance of a microdeletion in a novel pseudogene and a
known FAAH hypomorphic SNP. The microdeletion is flanked
by repeated sequences that likely predispose the region to
genomic rearrangements, as seen in other genomic disor-
ders.25 Consequently, there are likely to be additional similar
individuals in the general population. The likelihood that this
disorder has been under-reported is highlighted by the fact
that the patient was diagnosed at age 66 yr despite a recurrent
history of painless injuries. Lipid profiling in peripheral blood
showed significant increases in AEA, OEA, and PEA, which
could be further exaggerated in the brain and DRG. Further
work is needed to understand which FAA is the major
contributor to the painless phenotype.
The microdeletion removes the promoter and first two
exons of FAAH-OUT, but how this disrupts the function of
FAAH is still to be elucidated. A hypothesis is that the FAAH-
OUT transcript normally functions as a decoy for microRNAs
as a result of the high sequence homology, and protects FAAH
mRNA from degradation (Supplementary Fig. S7).26 Alterna-
tively, FAAH-OUT may have an epigenetic role in regulating
FAAH transcription, or the deletion removes a critical tran-
scriptional regulatory element.25,27 Future work will help us to
understand whether targeting FAAH-OUT by viral shRNA or
gene editing techniques is an effective analgesic/anxiolytic
drug development strategy.
This patient provides new insights into the role of the
endocannabinoid system in analgesia andmore specifically on
the FAAH genomic locus, and highlights the importance of the
adjacent, previously uncharacterised FAAH-OUT gene to pain
sensation. Given the previous failure of FAAH-inhibitor anal-
gesic drug trials, this report has significance, as it provides a
new route to developing FAAH-related analgesia through
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